Calypte und die Zeit nach AIDS2004 in Bangkok

11:29:59 0,25  130.000  zu 0,25 !!!!!!!!!!!!!!!!!!!!!!!

Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy

Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy

Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy

calys, oder ???

Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy

resist. 0.30 2
supp 0.28 2
supp 0.27 12
supp 0.23 14
supp 0.22 9
supp 0.21 11
supp 0.20 35
supp 0.19 2
supp 0.18 13
supp 0.16 2
supp 0.15 10
supp 0.13 15

Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy

0.27 2000    SNX 15:59:52
0.27 2000    SNX 15:59:32
0.27 2000    SNX 15:59:28
0.27 2000    SNX 15:59:19
0.27 40000    AMX 15:56:35
0.27 600    AMX 15:56:32
0.28 2500    SNX 15:55:56
0.27 8000    SNX 15:55:40
0.27 2400    SNX 15:54:36
0.27 8000    PAC 15:54:36
0.27 100    PAC 15:54:36
0.27 100    PAC 15:54:36
0.28 500    SNX 15:53:47
0.28 10000    PAC 15:53:38
0.271 600    SNX 15:53:18
0.27 1500    NSX 15:51:47
0.27 500    NSX 15:51:47
0.27 21300    SNX 15:51:32
0.28 8700    NSX 15:51:32
0.28 16300    NSX 15:51:32
0.27 2900    SNX 15:51:29
0.27 2000    SNX 15:51:26
0.28 6400    AMX 15:51:22
0.28 8500    SNX 15:51:14
0.28 27300    SNX 15:51:11
0.28 200    SNX 15:50:58
0.28 22700    AMX 15:50:56
0.28 10000    SNX 15:50:39
0.28 50000    SNX 15:50:39

259100 Stück von Gesamtumsatz von 1.200.000 Stück ! hmmm

nach!

 8:42 AM Calypte's Aware(TM) HIV-1/2 BSP Test Receives Zimbabwe Approval Regulatory Trials Of Aware(TM) BSP Generate 100% Accuracy
Heute Up?

Calypte's Aware(TM) HIV-1/2 BSP Test Receives Zimbabwe Approval
         Regulatory Trials Of Aware(TM) BSP Generate 100% Accuracy
LAKE OSWEGO, Ore., Sept. 15 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (Amex: HIV) today announced that the Medical Laboratory & Clinical Scientists Council of Zimbabwe has issued notification that the Calypte Aware(TM) HIV-1/2 BSP rapid (blood) test has been successfully evaluated and cleared for commercial sale in Zimbabwe.

The Calypte Aware HIV-1/2 BSP rapid test was evaluated under the direction of the Medical Laboratory & Clinical Scientists Council of Zimbabwe on over 1,000 samples. Roughly half of the samples were archived samples from the national reference panel and the other half were collected prospectively from clinical patients, blood donors, and attendees at VCT (Voluntary testing and Counseling) sites. The clinical trial of the Aware HIV-1/2 BSP rapid test included 1,005 subjects; 224 of whom were infected and 781 of whom were uninfected. The table below summarizes the performance of the rapid tests.


                                 Sensitivity     Specificity     Accuracy
   Aware HIV-1/2 BSP
     Archived Samples (500)         100.0%          100.0%        100.0%
     Prospective Samples (505)      100.0%          100.0%        100.0%


Sensitivity is a measure of the number of infected subjects correctly identified as positive. Specificity is a measure of the number of uninfected subjects correctly identified as negative. Accuracy is a composite measure of how many of the test subjects were correctly classified as infected or uninfected.

Calypte and its distributor, National Diagnostics, are now working with authorities on a process by which Aware HIV-1/2 OMT (oral fluid) and HIV-1/2 U (urine) rapid assays can be evaluated. Zimbabwe has not had the opportunity to field test non-blood HIV screening tests before, and its standard approach to evaluate HIV antibody tests is not appropriate for samples such as urine and oral fluid. The authorities are examining various proposals for such an evaluation.

Dr. Richard George, President and CEO of Calypte said, "We are delighted that the BSP test has passed yet another regulatory hurdle, and we now look forward to working with National Diagnostics, our distributor in Zimbabwe, to get the product commercially launched. In parallel we hope to complete the evaluation using the Company's technology in Urine and Oral fluid."

Tony Mariani, President of National Diagnostics, added, "We are extremely pleased with the exceptional results achieved by the Aware BSP HIV-1/2 kit in its evaluation phases. We look forward to our venture with Calypte in the marketing and distribution of this kit throughout Zimbabwe. Since our establishment in 1991, National Diagnostics has imported and distributed a wide range of diagnostic reagents, and this project promises to be one of the most important undertakings in our company's history".

Zimbabwe, with a population of just under 13 million, has an estimated 1.8 million HIV infections, according to the UNAIDS 2004 Report on the Global AIDS Epidemic, ranking as the 3rd largest prevalence in Africa today.

Aware(TM) BSP is a twenty-minute rapid test designed to detect HIV antibodies in whole blood, serum, or plasma. It is one test in a line of three such assays, the other two being designed to detect HIV antibodies in oral fluid and urine.

About Calypte Biomedical:

Calypte Biomedical Corporation is a US-based healthcare company focused on the development and commercialization of diagnostic testing products for the detection of sexually transmitted diseases. Calypte specializes in novel tests such as the HIV-1 BED Incidence EIA and is engaged in developing and commercializing new diagnostic test products for the rapid detection of HIV and other sexually transmitted diseases, several of which do not require blood samples. Calypte believes that there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in lesser-developed countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing, if and as needed, and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB/A (No. 2) for the year ended December 31, 2004 and its subsequent filings with the SEC.

Investor Relations Contact:

Tim Clemensen-212-843-9337

tclemensen@rubensteinir.com

SOURCE  Calypte Biomedical Corporation
   -0-                             09/15/2005
   /CONTACT:  Investor Relations, Tim Clemensen, +1-212-843-9337,
tclemensen@rubensteinir.com, for Calypte Biomedical/
   /Web site:  http://www.calypte.com/
   (HIV)

CO:  Calypte Biomedical Corporation
ST:  Oregon, Zimbabwe
IN:  HEA MTC BIO
SU:  BLK

AS
-- NYTH040 --
2935 09/15/2005 08:41 EDT http://www.prnewswire.com

Staate. Werde wohl schnell nachkaufen. Caly laeuft nun wohl endlich richtig an!

laeuft jetzt endlich richtig an. Die Nachrichtenlage konzentriert sich; das Ergebnis in Zimbabwe ist bestens und andere afrik. Laender in der Region werden mit dem Resultat auch hochzufrieden sein. Ich erwarte in Kuerze wesentlich sales-Nachrichten.
Viel Glueck uns allen dabei - koennte uns sehr gut tun was kommen wird!

ihr solltet nicht auf den broker hören. zum jahresende hat sich hier nichts verdoppelt oder verdreufacht. darauf verwtte ich mein haus.

spätestens zum 15.11, wenn die q-3-zahlen da sind, seid ihr unter 0,20$. der werden keine aufträge kommen. wie ich schon vor ein paar tagen schrieb: es läuft pump an dump momentan, wisst ihr eigentlich, weiviel neue aktien, bei den warmduschermeldungen abgeladen werden?

die wirkung hält max. 1-2 tage vor.

ich hätte selber nicht gedacht, dass ihr nochmal diese verkaufsmöglichkeit bekommen würdet. nutzt die gunst der stunde und verscheuert eure teile, ihr werdet es sonst bitterlich bereuen. wenn der broker hält, soll er alleine pleite gehen. von börse hat der jedenfalls keine ahnung.

die warmduschermeldungen ohne umsatz werden bald auch nicht mehr ziehen, garantiert!!!

bis zum jahres ende habt ihr die 0,10$ gesehen, versprochen. ihr werdet noch an meine worte denken!!!

hier könnt ihr mal sehen, wieviel teile in den letzten monaten von den insties geworfen wurden!!!!!!!!!1

current: über 6 mio. teile!!! gekauft wurden nur 78.t. die stammen wohl von broker und kade!!! muhahahahahah

das heißt nichts gutes. auch wenn ihr es jetzt wieder nicht glauben wollt, wie die filings!!!



HIV PROFILE

» Overview
» Insiders
» Institutional
» Split Factor
» Short Interest
» High/Low/Close
Name: CALYPTE BIOMEDICAL Address: 5 Centerpointe Dr Suite 400
Telephone: (971) 204-0282 Website: www.calypte.com
Facsimile: (925) 814-8408 Email: hervdoc@aol.com
Business Description: The business involves the development, manufacture and marketing of in vitro diagnostic tests primarily for the detection of antibodies to the Human Immunodeficiency Virus (´HIV´ and other sexually transmitted and infectious diseases.
Details
CEO: J. Richard George
Employees: 63
Issue Type: CS
Market Cap: 53767294
Auditor: Odenberg, Ullakko, Muranishi & Co. LLP
Last Audit: UQ
Industry Classifications
Sector: TECHNOLOGY Sub Sector: ELECTRONICS
Industry: Scientific & Technical Instruments CIK: 0000899426
Profitability Management Effectiveness
Gross Margin: NC Return on Equity: NE
EBIT Margin: NC Return on Capital: 563.7
Profit Margin: NC Return on Assets: -173.7
Share Statistics
Outstanding: 179224314 Float: 178531564
Short Interest: 209165
Short Int Ratio: 0.3 % of Float: 0.1
Non-Corp. Insider Hold´gs: 14
Bought Prev 3 Mo: 0 Sold Prev 3 Mo: 0
Institution Hold´gs: 2005/08
Total Held: 10413654 Institutions: 14
Bought Prev Mo: 6234053 Sold Prev Mo: 70962
Bought Prev Mo: 6234053 Sold Prev Mo: 70962
Pct Of Shares Outstanding Held By Insiders: 0.4 Pct Of Shares Outstanding Held By Institutions: 5.8
Short Interest As Perent Of Float 0.1

Brought to you by: AlphaTrade.com
Data provided by: Hemscott Americas

HIV PROFILE

» Overview
» Insiders
» Institutional
» Split Factor
» Short Interest
» High/Low/Close

Institutional

1)Institutional Holdings Date 2)# Institutional Shares Bought
3)# Institutional Shares Sold
4)Shares Held By Institutions
5)# Institutions Holding Shares

1) 2) 3) 4) 5)

Eleven Months Ago 2004/09 3358400 295000 13.744.277 10
Ten Months Ago 2004/10 3193000 295000 13.744.277 10
Nine Months Ago 2004/11 3193000 300000 11.728.277 12
Eight Months Ago 2004/12 3193000 300000 12.009.177 12
Seven Months Ago 2005/01 0 1175500 11.210.677 13
Six Months Ago 2005/02 0 875875 21.218.893 16
Five Months Ago 2005/03 0 3797875 17.435.393 15
Four Months Ago 2005/04 0 3802675 17.432.893 16
Three Months Ago 2005/05 1248864 2803870 18.678.745 17
Two Months Ago 2005/06 1248864 1695470 17.002.645 17
One Month Ago 2005/07 497864 1695470 15.225.645 15
Current 2005/08 70962 6234053 10.413.654 14

Brought to you by: AlphaTrade.com
Data provided by: Hemscott Americas